Search the Newsreel

(XNCR) as a Liquidity Pulse for Institutional Tactics

This article analyzes Xencor Inc. (NASDAQ: XNCR) based on AI models, identifying strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It presents three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored …

Xencor stock hits 52-week high at 21.99 USD

Xencor Inc. (XNCR) has reached a new 52-week high of $21.99, demonstrating a 41% year-to-date return and a 178.71% increase over the past year, reflecting strong investor confidence in the biotechnology company. This growth is attributed to its innovative work in engineered monoclonal antibodies …

Xencor Inc (XNCR) Earnings Forecast: Future EPS & Revenue Growth Estimates

Xencor (XNCR) Could Be 24% Below Fair Value On Narrower Quarterly Loss

Xencor (XNCR) recently reported a narrower quarterly net loss, reinforcing positive sentiment and leading to significant share price returns over the last month and year. Despite negative 3- and 5-year returns, the company is considered 24.3% undervalued with a fair value of $28.50 compared …

Analysts Are Upgrading Xencor, Inc. (NASDAQ:XNCR) After Its Latest Results

Xencor, Inc. (NASDAQ:XNCR) recently released a strong quarterly report, with revenue significantly beating expectations and losses being smaller than predicted. This positive performance has led analysts to upgrade their revenue estimates for 2026 and reduce loss estimates, though the consensus price target remains unchanged. …

How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit

Xencor, Inc. has reported its second-quarter 2026 results, with net loss improving to US$21.73 million versus US$30.83 million a year earlier, while basic and diluted loss per share from continuing operations narrowed to US$0.29 from US$0.41. Over the first half of 2026, however, Xencor's …

Xencor, Inc. Stock 12‑Month Price Target Raised to $29, Implies 45% Upside

Xencor, Inc. (XNCR) has seen its average 12-month price target raised from $28.75 to $29 by 12 analysts, implying a 45% potential upside from its Aug. 6 closing price. The consensus rating for the stock remains "Buy" among 14 analysts, with 12 recommending a …

Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen has upgraded Xencor (NASDAQ:XNCR) from "strong sell" to "hold" after the company reported better-than-expected quarterly results, including a smaller loss per share and significantly higher revenue than anticipated. Despite the upgrade and several bullish analyst price targets, the broader analyst consensus …

Xencor Inc (XNCR) Stock News Today

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages

Xencor, Inc. (NASDAQ:XNCR) has received a consensus "Hold" recommendation from brokerages, with nine firms providing ratings. The biopharmaceutical company recently reported a quarterly loss of $0.29 per share, exceeding analyst estimates, and saw its revenue increase by 17.4% year over year. Several institutional investors …

Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

Xencor, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting advancements in its oncology and autoimmune disease pipelines. Key updates include the progress of XmAb819 in clinical trials for various cancers, the advancement of XmAb942 and …

Does Xencor’s Mixed 2026 Loss Trend Reshape the Investment Narrative Around XNCR’s R&D Priorities?

Xencor, Inc. reported mixed Q2 and half-year 2026 results, with a narrowing net loss for the quarter but a widened net loss for the first six months. This financial divergence highlights the impact of R&D spending on the company's profile and prompts a re-evaluation …

Xencor (NASDAQ:XNCR) Hits New 52-Week High Following Better-Than-Expected Earnings

Xencor (NASDAQ:XNCR) shares reached a new 52-week high after reporting better-than-expected quarterly earnings and revenue. The biopharmaceutical company posted an EPS of $(0.29), significantly beating the consensus estimate of $(0.80), and revenue of $51.22 million, surpassing expectations. Despite remaining unprofitable with a negative net …

Xencor Inc 2Q 2026: Revenue $51.22M, EPS ($0.29) — 10-Q Summary

Xencor Inc reported its second-quarter 2026 results, showing a revenue increase to $51.22 million from $43.61 million year-over-year. Despite the revenue growth, the company posted a net loss of ($21.73 million) and a diluted loss per share of ($0.29). Key drivers included higher royalties …

Xencor (XNCR) Stock Drifts As Revenue Lands But Profit Path Stays Murky

Xencor Reports Second Quarter 2026 Financial Results

Xencor, Inc. reported its second-quarter 2026 financial results, highlighting significant progress in its clinical pipeline and strategic partnerships. Key updates include planned presentations for XmAb819 at ESMO 2026, continued enrollment for XmAb942 in the XENITH-UC study, and the initiation of a first-in-human study for …

Xencor Inc earnings beat by $0.51, revenue topped estimates

Xencor (NASDAQ: XNCR) nets $105M Alexion settlement as Q2 2026 loss hits $21.7M

Xencor (NASDAQ: XNCR) reported a Q2 2026 net loss of $21.7 million, narrowing from $30.8 million in Q2 2025, on revenues of $51.2 million. The company also announced a post-quarter-end settlement with Alexion for $105 million, resolving a U.S. royalty dispute related to Ultomiris …

Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.51 EPS

Xencor (NASDAQ:XNCR) reported quarterly EPS of ($0.29), significantly beating analyst expectations of ($0.80) by $0.51, despite maintaining a negative net margin. The biopharmaceutical company's shares traded near $19.84, close to its 52-week high, with major institutional investors like Goldman Sachs and JPMorgan increasing their …

Xencor: Q2 Earnings Snapshot

Xencor Inc. reported a Q2 loss of $21.7 million, or 29 cents per share, which surpassed Wall Street's expectation of an 82-cent loss per share. The biotech company also posted revenue of $51.2 million, significantly beating the Street forecast of $11.7 million. These results …

Xencor (XNCR) Earnings Date and Reports 2026

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates

Xencor faces earnings test after revenue miss rocks biotech By Investing.com

Xencor, a clinical-stage biopharmaceutical company, is set to report its second-quarter results as investors seek signs of revenue recovery after a significant first-quarter miss. Analysts anticipate a loss of $0.81 per share on $17.51 million in revenue, an improvement from the previous quarter but …

Xencor (XNCR) Could Be 29% Undervalued Following Its Sharp Single Day Move

Xencor (XNCR) recently experienced a sharp single-day stock move

(XNCR) Risk Channels and Responsive Allocation

This article analyzes Xencor Inc. (XNCR) using AI models to identify strong sentiment across all horizons, supporting an overweight bias. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis …

XNCR|Xencor Inc|Price:20.220|Chg%:-1.270

This article provides a comprehensive stock analysis of Xencor Inc (XNCR), highlighting its stable fundamentals, significant growth potential, and "fairly valued" status. It notes high institutional ownership and multiple analyst "Buy" ratings with a target price of $29.64. The company, a clinical-stage biopharmaceutical firm, …

Xencor Secures Ultomiris Royalty Settlement Payment

Xencor announced a settlement agreement with Alexion Pharma International Operations regarding U.S. royalties on Ultomiris, securing $105 million in two installments. This agreement eliminates Alexion’s future U.S. royalty obligations while preserving ex-U.S. royalties. The capital effectively replaces anticipated U.S. royalty income through 2028, extending …

Vanguard Capital Management (XNCR) discloses 3.8M-share, 5.13% stake in Xencor

Vanguard Capital Management has disclosed a 5.13% passive stake in Xencor Inc. (XNCR), holding 3,810,823 shares of common stock. This ownership is reported across various Vanguard funds and managed accounts, with Vanguard exercising sole voting power over 532,021 shares and sole dispositive power over …

Xencor (XNCR) Reiterated by Wedbush -- Rating Maintained at Outp

Wedbush has reiterated its Outperform rating for Xencor (XNCR) with a maintained price target of $26.00, reflecting confidence in its future performance. However, GuruFocus's GF Value™ indicates the stock is significantly overvalued at $19.91 compared to its intrinsic value of $9.13, and its GF …

Xencor Shares Rise After Settlement Deal With Alexion

Xencor shares increased following a settlement deal with Alexion, a subsidiary of AstraZeneca. The agreement resolves litigation related to Xencor's bispecific antibody, XmAb11516, which targets the C5 protein, the same target as Alexion's Soliris and Ultomiris. Under the deal, Xencor will pay Alexion royalties …

Xencor (NASDAQ:XNCR) Reaches New 1-Year High - Should You Buy?

Xencor (NASDAQ:XNCR) shares recently reached a new 52-week high of $21.64, closing at $21.32, marking a 10.1% gain for the session. Despite this stock performance, the company reported significant weakness in its latest quarter, with an EPS loss of $1.71 against an expected $0.75 …

Xencor rises as AstraZeneca royalty row ends (XNCR:NASDAQ)

Xencor (XNCR) shares rose after settling a royalty dispute with Alexion Pharma, a subsidiary of AstraZeneca (AZN). The dispute was related to Ultomiris, a rare disease therapy. Xencor had previously lowered its operating outlook in March due to this issue.

Wedbush Reiterates Outperform Rating for Xencor (NASDAQ:XNCR)

Wedbush has reiterated an "outperform" rating for Xencor (NASDAQ:XNCR) and maintained a $26 price target, suggesting a 30.4% upside. Despite this positive outlook, the biopharmaceutical company reported weak Q1 earnings, missing revenue and EPS estimates significantly. Analyst sentiment remains mixed, with a "Moderate Buy" …